v3.26.1
Note 19 - Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
      

As of December 31, 2025

     
  

Biopharma

  

CDMO

  

Consolidated

 

Cash and cash equivalents

 $12,277  $368  $12,645 

Prepaid expenses and other current assets

  156   190   346 

Property and equipment, net

  34   12,607   12,641 

Deferred offering costs

  136      136 

Licensed technology, net

  2,243      2,243 

Goodwill

     3,457   3,457 

Other assets

  124      124 

Total consolidated assets of continuing operations

 $14,970  $16,622  $31,592 
      

For the year ended December 31, 2025

     
  

Biopharma

  

CDMO

  

Consolidated

 

Operating expenses:

            

Research and development

 $2,776  $355  $3,131 

Selling, general and administrative

  4,575   192   4,767 

Total operating expenses

  7,351   547   7,898 

Other (expense) income:

            

Change in fair value of derivative liability

  28      28 

Interest income

  23      23 

Interest expense

  (146)     (146)

Net other expense

  (95)     (95)

Net loss from operations before discontinued operations

 $(7,446) $(547) $(7,993)